Fig. 3

The subgroup analysis of adjuvant ET in ER+/PR- patients. Adjuvant ET cannot improve DFS of ER+/PR- patients in each subgroup. ET, endocrine treatment; HR, hazard ratio; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; RT, radiation therapy; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.